Intraductal administration of a polymeric nanoparticle formulation of curcumin (NanoCurc) significantly attenuates incidence of mammary tumors in a rodent chemical carcinogenesis model: Implications for breast cancer chemoprevention in at-risk populations

Carcinogenesis

Volumn 33, Issue 11, 2012, Pages 2242-2249

  Chun, Yong Soon ^a,b   Bisht, Savita ^a   Chenna, Venugopal ^a   Pramanik, Dipankar ^a   Yoshida, Takahiro ^a   Hong, Seung Mo ^a   De wilde, Roeland F ^a   Zhang, Zhe ^a   Huso, David L ^a   Zhao, Ming ^a   Rudek, Michelle A ^a   Stearns, Vered ^a   Maitra, Anirban ^a   Sukumar, Saraswati ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Gachon University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHYLNITROSOUREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER INCIDENCE; CANCER PREVENTION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG MEGADOSE; FEMALE; HIGH RISK POPULATION; HISTOPATHOLOGY; INTRADUCTAL DRUG ADMINISTRATION; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; STATISTICAL SIGNIFICANCE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CURCUMIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; IMMUNOENZYME TECHNIQUES; INCIDENCE; MAMMARY NEOPLASMS, EXPERIMENTAL; METHYLNITROSOUREA; NANOPARTICLES; POLYMERS; RATS; RATS, SPRAGUE-DAWLEY; SURVIVAL RATE; TISSUE DISTRIBUTION;

EID: 84868628559     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs248     Document Type: Article

References (44)

1. Wooster, R. et al. (2003) Breast and ovarian cancer. N. Engl. J. Med., 348, 2339-2347.
2. Robson, M. et al. (2007) Clinical practice. Management of an inherited predisposition to breast cancer. N. Engl. J. Med., 357, 154-162.
3. Murata, S. et al. (2006) Ductal access for prevention and therapy of mammary tumors. Cancer Res., 66, 638-645.
4. Stearns, V. et al. (2011) Preclinical and clinical evaluation of intraductally administered agents in early breast cancer. Sci. Transl. Med., 3, 106-108.
5. Aggarwal, B.B. et al. (2003) Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res., 23, 363-398.
6. Strimpakos, A.S. et al. (2008) Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid. Redox. Signal, 10, 511-545.
7. Ravindran, J. et al. (2009) Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS. J., 11, 495-510.
8. Shishodia, S. et al. (2007) Role of curcumin in cancer therapy. Curr. Probl. Cancer, 31, 243-305.
9. Aggarwal, B.B. et al. (2005) Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin. Cancer Res., 11, 7490-7498.
10. Labbozzetta, M. et al. (2009) Curcumin as a possible lead compound against hormone-independent, multidrug-resistant breast cancer. Ann. N. Y. Acad. Sci., 1155, 278-283.
11. Shao, Z.M. et al. (2002) Curcumin exerts multiple suppressive effects on human breast carcinoma cells. Int. J. Cancer, 98, 234-240.
12. Rowe, D.L. et al. (2009) Modulation of the BRCA1 protein and induction of apoptosis in triple negative breast cancer cell lines by the polyphenolic compound curcumin. Breast Cancer (Auckl), 3, 61-75.
13. Jiang, M.C. et al. (1996) Curcumin induces apoptosis in immortalized NIH 3T3 and malignant cancer cell lines. Nutr. Cancer, 26, 111-120.
14. Syng-Ai, C. et al. (2004) Effect of curcumin on normal and tumor cells: role of glutathione and bcl-2. Mol Cancer Ther, 3, 1101-1108.
15. Ramachandran, C. et al. (1999) Differential sensitivity of human mammary epithelial and breast carcinoma cell lines to curcumin. Breast Cancer Res. Treat., 54, 269-278.
16. Garcea, G. et al. (2005) Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol. Biomarkers Prev., 14, 120-125.
17. Sharma, R.A. et al. (2004) Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin. Cancer Res., 10, 6847-6854.
18. Lao, C.D. et al. (2006) Dose escalation of a curcuminoid formulation. BMC Complement Altern. Med., 6, 10.
19. Cheng, A.L. et al. (2001) Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res., 21, 2895-2900.
20. Anand, P. et al. (2007) Bioavailability of curcumin: problems and promises. Mol. Pharm., 4, 807-818.
21. Bisht, S. et al. (2009) Systemic delivery of curcumin: 21st century solutions for an ancient conundrum. Curr. Drug Discov. Technol., 6, 192-199.
22. Bisht, S. et al. (2010) Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer. Mol. Cancer Ther., 9, 2255-2264.
23. Thompson, H.J. et al. (2000) Classification of premalignant and malignant lesions developing in the rat mammary gland after injection of sexually immature rats with 1-methyl-1-nitrosourea. J. Mammary Gland Biol. Neoplasia, 5, 201-210.
24. Thompson, H.J. et al. (1998) Temporal sequence of mammary intraductal proliferations, ductal carcinomas in situ and adenocarcinomas induced by 1-methyl-1-nitrosourea in rats. Carcinogenesis, 19, 2181-2185.
25. Bisht, S. et al. (2011) A polymeric nanoparticle formulation of curcumin (NanoCurc) ameliorates CCl(4)-induced hepatic injury and fibrosis through reduction of pro-inflammatory cytokines and stellate cell activation. Lab. Invest., 91, 1383-1395.
26. Ray, B. et al. (2011) Neuroprotective and neurorescue effects of a novel polymeric nanoparticle formulation of curcumin (NanoCurc) in the neuronal cell culture and animal model: implications for Alzheimer's disease. J. Alzheimers Dis., 23, 61-77.
27. Bailer, A.J. (1988) Testing for the equality of area under the curves when using destructive measurement techniques. J. Pharmacokinet. Biopharm., 16, 303-309.
28. Hartmann, L.C. et al. (1999) Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N. Engl. J. Med., 340, 77-84.
29. Chlebowski, R.T. et al. (1999) American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. J. Clin. Oncol., 17, 1939-1955.
30. Visvanathan, K. et al. (2009) American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol, 27, 3235-3258.
31. Jemal, A. et al. (2010) Cancer statistics, 2010. CA Cancer J. Clin., 60, 277-300.
32. Waters, E.A. et al. (2010) Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women. Cancer Epidemiol. Biomarkers Prev., 19, 443-446.
33. Blaha, P. et al. (2009) Breast cancer chemoprevention-a vision not yet realized. Eur. J. Cancer Care (Engl), 18, 438-446.
34. Nelson, H.D. et al. (2009) Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer. Ann. Intern. Med., 151, 703-715, W226-235.
35. Singletary, K. et al. (1996) Inhibition of 7, 12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumorigenesis and DMBA-DNA adduct formation by curcumin. Cancer Lett, 103, 137-141.
36. Carroll, C.E. et al. (2010) Curcumin delays development of medroxyprogesterone acetate-accelerated 7, 12-dimethylbenz[a]anthracene-induced mammary tumors. Menopause, 17, 178-184.
37. Shoba, G. et al. (1998) Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med., 64, 353-356.
38. Li, L. et al. (2005) Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer, 104, 1322-1331.
39. Maiti, K. et al. (2007) Curcumin-phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. Int. J. Pharm., 330, 155-163.
40. Bao, B. et al. (2012) Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res., 72, 335-345.
41. Bisht, S. et al. (2007) Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J. Nanobiotechnology, 5, 3.
42. Jacobs, L. et al. (2010) Intraductal therapy for the prevention of breast cancer. Curr. Opin. Investig. Drugs, 11, 646-652.
43. Aggarwal, B.B. et al. (2004) Suppression of the nuclear factor-kappaB activation pathway by spice-derived phytochemicals: reasoning for seasoning. Ann. N. Y. Acad. Sci., 1030, 434-441.
44. Anand, P. et al. (2008) Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem. Pharmacol., 76, 1590-1611.